Successful Treatment with Adalimumab for Intestinal Behcet's Disease during Pregnancy

Keita Fujikawa; Yushiro Endo; Akinari Mizokami; Kosuke Takahashi; Maiko Tabuchi; Kazuo Ohba; Hideki Nakamura; Atsushi Kawakami

doi:10.2169/internalmedicine.55.6590

CASE REPORTS

Successful Treatment with Adalimumab for Intestinal Behcet's Disease during Pregnancy

Keita Fujikawa, Yushiro Endo, Akinari Mizokami, Kosuke Takahashi, Maiko Tabuchi, Kazuo Ohba, Hideki Nakamura, Atsushi Kawakami

Author information

Keita Fujikawa
Department of Rheumatology, Japan Community Healthcare Organization (JCHO), Isahaya General Hospital, Japan
Yushiro Endo
Department of Rheumatology, Japan Community Healthcare Organization (JCHO), Isahaya General Hospital, Japan
Akinari Mizokami
Department of Rheumatology, Japan Community Healthcare Organization (JCHO), Isahaya General Hospital, Japan
Kosuke Takahashi
Department of Gastroenterology, Japan Community Healthcare Organization (JCHO), Isahaya General Hospital, Japan
Maiko Tabuchi
Department of Gastroenterology, Japan Community Healthcare Organization (JCHO), Isahaya General Hospital, Japan
Kazuo Ohba
Department of Gastroenterology, Japan Community Healthcare Organization (JCHO), Isahaya General Hospital, Japan
Hideki Nakamura
Department of Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Japan
Atsushi Kawakami
Department of Rheumatology, Unit of Translational Medicine, Graduate School of Biomedical Sciences, Nagasaki University, Japan

Keywords: adalimumab, intestinal Behcet's disease, pregnancy, placental transition

JOURNAL OPEN ACCESS

2016 Volume 55 Issue 10 Pages 1375-1378

DOI https://doi.org/10.2169/internalmedicine.55.6590

Details

Abstract

A 36-year-old Japanese woman with intestinal Behcet's disease was admitted to our hospital due to a recurrent ileocecal ulcer. Because infliximab (IFX) showed secondary failure, IFX was switched to adalimumab (ADA). After the third injection of ADA, she was unexpectedly 4-weeks pregnant. ADA was continued until 20 gestational weeks. Remission of the disease activity was maintained during pregnancy, and the birth was uneventful. The ileocecal ulcer disappeared after her delivery. ADA was detected in the umbilical blood after 119 days from the last infusion. The placental transition and timing of neonatal vaccination should be considered in cases of pregnancy with TNF antibody therapy.

Corresponding author

Register with J-STAGE for free!